GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » PEG Ratio

Square Pharmaceuticals (DHA:SQURPHARMA) PEG Ratio : 1.07 (As of Jul. 20, 2025)


View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Square Pharmaceuticals's PE Ratio without NRI is 8.01. Square Pharmaceuticals's 5-Year EBITDA growth rate is 7.50%. Therefore, Square Pharmaceuticals's PEG Ratio for today is 1.07.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Square Pharmaceuticals's PEG Ratio or its related term are showing as below:

DHA:SQURPHARMA' s PEG Ratio Range Over the Past 10 Years
Min: 0.43   Med: 0.84   Max: 4.52
Current: 1.07


During the past 13 years, Square Pharmaceuticals's highest PEG Ratio was 4.52. The lowest was 0.43. And the median was 0.84.


DHA:SQURPHARMA's PEG Ratio is ranked better than
68.18% of 352 companies
in the Drug Manufacturers industry
Industry Median: 1.685 vs DHA:SQURPHARMA: 1.07

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Square Pharmaceuticals PEG Ratio Historical Data

The historical data trend for Square Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals PEG Ratio Chart

Square Pharmaceuticals Annual Data
Trend Mar15 Mar16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.49 0.97 0.82 0.85

Square Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.85 0.97 0.91 0.90

Competitive Comparison of Square Pharmaceuticals's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Square Pharmaceuticals's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's PEG Ratio falls into.


;
;

Square Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Square Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=8.0103747697628/7.50
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Square Pharmaceuticals  (DHA:SQURPHARMA) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Square Pharmaceuticals PEG Ratio Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Square Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.

Square Pharmaceuticals Headlines

No Headlines